Search research articles
Contact Us
Filters
Showing results (41-50 of 124) with videos related to
Page
of 13
Sort By:
Investigational New Drugs
|
November 6, 2004
Phase I study of liposomal doxorubicin (Doxil) and cyclophosphamide in solid tumors
Basil F El-Rayes, Dina Ibrahim, Anthony F Shields, et al.
Cancer Genetics and Cytogenetics
|
November 14, 1997
Cytogenetic aberrations and DNA ploidy in soft tissue sarcoma. A Southwest Oncology Group Study
A N Mohamed, M M Zalupski, J R Ryan, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy
|
October 1, 1994
Phase II trial of recombinant human macrophage colony-stimulating factor in metastatic soft tissue sarcoma
F A Momin, M Zalupski, L K Heilbrun, et al.
American Journal of Clinical Oncology
|
November 5, 2015
A Phase II Study of Biweekly Cisplatin, Fixed-Dose-Rate Gemcitabine and Infusional 5-Fluorouracil in Patients With Metastatic Pancreatic and Biliary Cancers
Elizabeth J Davis, Kent A Griffith, Edward J Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 24, 2001
A phase II trial of bryostatin 1 in the treatment of metastatic colorectal cancer
J A Zonder, A F Shields, M Zalupski, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 7, 2012
VEGF remains an interesting target in advanced pancreas cancer (APCA): results of a multi-institutional phase II study of bevacizumab, gemcitabine, and infusional 5-fluorouracil in patients with APCA
L K Martin, X Li, B Kleiber, et al.
Investigational New Drugs
|
September 18, 1998
Evaluation of pyrazoloacridine in patients with advanced pancreatic carcinoma
M M Zalupski, A F Shields, P A Philip, et al.
The Oncologist
|
July 22, 2024
PARP inhibitor therapy in patients with IDH1 mutated cholangiocarcinoma
Arathi Mohan, Elit Quingalahua, Valerie Gunchick, et al.
American Journal of Clinical Oncology
|
August 24, 2000
Cisplatin, cytarabine, caffeine, and continuously infused 5-fluorouracil (PACE) in the treatment of advanced pancreatic carcinoma: a phase II study
S Ahmed, V K Vaitkevicius, M M Zalupski, et al.
Investigational New Drugs
|
November 1, 1993
Phase II trial of piroxantrone for advanced or metastatic soft tissue sarcomas. A Southwest Oncology Group study
M M Zalupski, J Benedetti, S P Balcerzak, et al.
Page
of 13
Search research articles
Search
Showing results (41-50 of 124) with videos related to
Sort By:
Page
of 13
Investigational New Drugs
|
November 6, 2004
Phase I study of liposomal doxorubicin (Doxil) and cyclophosphamide in solid tumors
Basil F El-Rayes, Dina Ibrahim, Anthony F Shields, et al.
Cancer Genetics and Cytogenetics
|
November 14, 1997
Cytogenetic aberrations and DNA ploidy in soft tissue sarcoma. A Southwest Oncology Group Study
A N Mohamed, M M Zalupski, J R Ryan, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy
|
October 1, 1994
Phase II trial of recombinant human macrophage colony-stimulating factor in metastatic soft tissue sarcoma
F A Momin, M Zalupski, L K Heilbrun, et al.
American Journal of Clinical Oncology
|
November 5, 2015
A Phase II Study of Biweekly Cisplatin, Fixed-Dose-Rate Gemcitabine and Infusional 5-Fluorouracil in Patients With Metastatic Pancreatic and Biliary Cancers
Elizabeth J Davis, Kent A Griffith, Edward J Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 24, 2001
A phase II trial of bryostatin 1 in the treatment of metastatic colorectal cancer
J A Zonder, A F Shields, M Zalupski, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 7, 2012
VEGF remains an interesting target in advanced pancreas cancer (APCA): results of a multi-institutional phase II study of bevacizumab, gemcitabine, and infusional 5-fluorouracil in patients with APCA
L K Martin, X Li, B Kleiber, et al.
Investigational New Drugs
|
September 18, 1998
Evaluation of pyrazoloacridine in patients with advanced pancreatic carcinoma
M M Zalupski, A F Shields, P A Philip, et al.
The Oncologist
|
July 22, 2024
PARP inhibitor therapy in patients with IDH1 mutated cholangiocarcinoma
Arathi Mohan, Elit Quingalahua, Valerie Gunchick, et al.
American Journal of Clinical Oncology
|
August 24, 2000
Cisplatin, cytarabine, caffeine, and continuously infused 5-fluorouracil (PACE) in the treatment of advanced pancreatic carcinoma: a phase II study
S Ahmed, V K Vaitkevicius, M M Zalupski, et al.
Investigational New Drugs
|
November 1, 1993
Phase II trial of piroxantrone for advanced or metastatic soft tissue sarcomas. A Southwest Oncology Group study
M M Zalupski, J Benedetti, S P Balcerzak, et al.
Page
of 13